Risk Factors for Developmental Dysplasia of the Hip Before 3 Months of Age: A Meta-Analysis

Maria Tirta1, Ole Rahbek1, Søren Kold1

  • 1Interdisciplinary Orthopaedics, Department of Orthopaedic Surgery, Aalborg University Hospital, Aalborg, Denmark.

JAMA Network Open
|January 24, 2025
PubMed

Insights

Family history and breech presentation significantly increase the risk of developmental dysplasia of the hip (DDH) in infants under 3 months. Female sex also poses a risk, though lower than previously thought.

Area of Science:

  • Pediatric Orthopedics
  • Diagnostic Imaging
  • Epidemiology

Background:

  • Previous meta-analyses identified breech presentation, family history of DDH, female sex, and primiparity as risk factors for DDH.
  • Variations in DDH definitions, reference tests, and patient age in prior studies complicated guideline development.

Purpose of the Study:

  • To evaluate the association between previously proposed risk factors and the risk of sonography-verified developmental dysplasia of the hip (DDH).

Main Methods:

  • A comprehensive literature search was conducted in PubMed, Embase, and the Cochrane Library.
  • Included studies were published between 1980 and 2023, involving infants under 3 months diagnosed with DDH via Graf method ultrasonography.
  • Data extraction followed PRISMA and MOOSE guidelines, focusing on risk factors and DDH outcomes using odds ratios (ORs).

Main Results:

  • Twenty studies including 64,543 infants were analyzed.
  • Significant risk factors for DDH included breech presentation (OR, 4.15), family history (OR, 3.83), female sex (OR, 2.50), oligohydramnios (OR, 3.76), and high birth weight (OR, 2.00).
  • Primiparity, Cesarean delivery, multiple births, low birth weight, and prematurity were not associated with increased DDH risk.

Conclusions:

  • Family history and breech presentation are strongly associated with an increased risk of sonography-verified DDH in infants younger than 3 months.
  • The increased risk associated with female sex is lower than previously reported.
  • Oligohydramnios is identified as a risk factor and may warrant consideration for screening programs.
Abstract

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.3K
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
36
Neurulation01:30

Neurulation

Neurulation is the embryological process which forms the precursors of the central nervous system and occurs after gastrulation has established the three primary cell layers of the embryo: ectoderm, mesoderm, and endoderm. In humans, the majority of this system is formed via primary neurulation, in which the central portion of the ectoderm—originally appearing as a flat sheet of cells—folds upwards and inwards, sealing off to form a hollow neural tube. As development proceeds, the...
41.6K